MRNA Stock Jumps As Nasdaq-100 Inclusion Meets Oncology Push

Moderna Inc. (MRNA) stock rose 10.78% on October 9, 2026, due to its inclusion in the Nasdaq-100 and optimism around its cancer pipeline. The company's revenue is $1.92B, but it reported a net loss of $782M and negative free cash flow. Analysts have mixed views, with targets ranging from $80 to $95. The stock's volatility is driven by technical factors and potential catalysts in oncology.

Moderna's stock rose 9% after the NYT reported a national cancer vaccine initiative involving NIH, pharma companies, and others. Moderna is seen as a leader in mRNA cancer treatments, with its stock up 627% YTD. Similar programs exist in the UK.

Moderna (MRNA) rose 5% to $207.80 after joining the NASDAQ 100, forcing index-tracking funds to buy shares. Pfizer (PFE) gained 0.7% to $28.02, and BioNTech (BNTX) increased 3% to $94.50. Moderna's addition is due to its shift from COVID-19 vaccines to oncology, with positive late-stage study results. The iShares Biotechnology ETF (IBB) rose 2%, outperforming the broader market.

Moderna (MRNA) shares rose over 9% to a 52-week high of $216.95 before retreating to $208.69, up 5.9%. The rally was driven by its re-inclusion in the Nasdaq-100 index and positive investor sentiment around its oncology pipeline. Analysts have mixed views, with Morgan Stanley raising its target to $95 and Citigroup downgrading to Sell with a $80 target.

FDA approved Moderna's Mflusiva, an mRNA flu vaccine, for adults 50+. It reduces flu risk by 26.6% vs. standard shots but has more side effects. Medicare covers it. Moderna must track safety long-term. Availability may be limited.

BofA Securities raised its price target for Moderna to $200 from $170, maintaining a neutral rating. The company's shares have risen 12.99% year-to-date and 628.04% over five years, according to the data.